Compare ACADIA Pharmaceuticals Inc. (ACAD) vs GraniteShares 2x Long COIN Daily ETF (CONL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs GraniteShares 2x Long COIN Daily ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.76 (market cap $4.49B), while GraniteShares 2x Long COIN Daily ETF trades at $5.03. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, GraniteShares 2x Long COIN Daily ETF nearer its low. Which is the better fit depends on your goals.
| ACAD | CONL | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $28.06 | $64.57 |
52-Week Low | $20.06 | $4.09 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
CONL trades at $5.62, up 4.07% today but remains a highly volatile leveraged ETF tracking Coinbase stock. Technical indicators show bearish momentum with mixed oscillators, while financial ratios are unavailable for this derivative product. Recent news highlights extreme volatility, with the fund losing 67% year-to-date as daily reset leverage magnifies Coinbase price swings.
The outlook remains speculative with potential for explosive gains if Coinbase rallies, but structural risks from daily leverage reset create significant volatility decay. Investors face amplified exposure to cryptocurrency market sentiment and Coinbase performance without traditional company fundamentals to anchor valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About GraniteShares 2x Long COIN Daily ETF
CONL is a leveraged ETF that seeks to provide two times (2x) the daily performance of Coinbase Global (COIN) stock. It is designed for investors seeking magnified short-term exposure to the price movements of Coinbase.
Read more on CONL →
